Stock info Astrazeneca | Filter Basic-Info
Stock: Astrazeneca (UK large caps), ISIN: GB0009895292
| Last Price | 10878.00 | Max Price | 12294.00 |
| Min Price | 9501.00 | 1 Year return | -3.03 |
| Avg. Target | 13230.00 | Expected Return | 21.62 % |
| Sector | Health Care | Subsector | Pharmaceuticals |
| Sell | 0 | Rating |
|
| Hold | 0 | Concensus |
|
| Buy | 5 | ||
| Annual report 2012 |
Astrazeneca is one of the world's leading pharmaceutical companies. Astrazeneca provides medicines designed to fight disease in important areas of medical need: cancer, cardiovascular, gastrointestinal, infections, neurosciences and respiratory. Astrazeneca’s stocks are traded in London and the company is a component of the FTSE 100-index (ISIN: GB0009895292/ Symbol: AZN).
Contact info:Street: 2 Kingdom StreetZip Code: London W2 City: LondonCountry: Great BritainPhone: 44 20 7604 8122Email: IR@astrazeneca.comWebsite: www.astrazeneca.co.uk
Sector Review Astrazeneca
| Year | Turnover | Total sector | Market share |
|---|---|---|---|
| 2019 | 24,384 | 615,634 | 3.96 % |
| 2020 | 26,617 | 638,070 | 4.17 % |
| 2021 | 37,417 | 727,968 | 5.14 % |
| 2022 | 44,351 | 787,273 | 5.63 % |
| 2023 | 0 | 0 | 0.00 % |
Advice Astrazeneca
News Astrazeneca
AstraZeneca signs deal to supply Canada 100k doses of COVID antibody therapy Evusheld
Analysts expect revenue increase Astrazeneca
AstraZeneca teams up with Scorpion Therapeutics to develop cancer treatments
AstraZeneca, Oxford start work on Omicron-specific COVID vaccine
Denmark to continuing banning J&J AstraZeneca vaccines
Annual reports Astrazeneca
| 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
Profile Astrazeneca
Astrazeneca
(GB0009895292)/ AZNThe past year yielded positive returns for Astrazeneca investors
The stock lost over the past 12 months at around 2 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 50 percent. Astrazeneca's revenues between 2011 and 2015 were relatively steady and moved between 1721,32 billion GBp and 1676,49 billion GBp. Astrazeneca's net results between 2011 and 2015 were quite unstable and moved between 563,16 billion GBp and 283,62 billion GBp.
Astrazeneca has it' headquarter based in London. Astrazeneca is mostly active in the pharmaceutical sector. The past 10 years the (international) industry gained at around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.
Over the past 5 years the English company paid out dividends. On average Astrazeneca's dividend yield over the past 5 years was around 1008,36 percent annually. Over the period 2011-2015 Astrazeneca raised it's dividends per share each year. So because of the yearly raised dividends per share Astrazeneca is a kind of dividend aristocrat.
Astrazeneca' balance mostly financed with equity
At the end of 2015 the pharmaceutical company's balance sheet was worth 4079,53 billion GBp. At the end of 2015 the total debt positon equaled 2824,95 billion GBp. This is around 69,25 percent of the total balance sheet. At the end of 2015 the pharmaceutical company's stock was traded with a price/earnings-ratio 20. So the stock' value was 20 times the 2015' earnings per share. We could say that based on her price/earnings-ratio and dividend yield the English stock can be seen as a value stock.
At the end of 2015 the English company's market capitalization equaled around 5835,26 billion GBp. At the end of 2015 around 1,26 billion stocks were listed.
All of Astrazeneca's annual reports are stored here. More information about Astrazeneca can be found it's website. .
Results Astrazeneca
| Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|---|
| Revenue |
24,708
|
23,002
|
22,465
|
22,090
|
24,384
|
26,617
|
| Costs |
21,883
|
19,503
|
19,464
|
19,935
|
23,049
|
23,421
|
| Profit |
2,825
|
3,499
|
3,001
|
2,155
|
1,335
|
3,196
|
| Margin of profit |
11.43
|
15.21
|
13.36
|
9.76
|
5.47
|
12.01
|
| ROI |
15.28
|
23.56
|
20.06
|
17.28
|
10.17
|
20.46
|
Balance Astrazeneca
| Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|---|
| Equity |
18,490
|
14,854
|
14,960
|
12,468
|
13,127
|
15,622
|
| Debt |
41,566
|
47,672
|
48,394
|
48,183
|
48,250
|
51,107
|
| Total assets |
60,056
|
62,526
|
63,354
|
60,651
|
61,377
|
66,729
|
| Solvency |
30.79
|
23.76
|
23.61
|
20.56
|
21.39
|
23.41
|
| Cash |
6,853
|
5,902
|
4,554
|
5,680
|
6,218
|
7,992
|
| Cashflow |
3,324
|
4,145
|
3,578
|
2,618
|
2,969
|
4,799
|
| Employees |
0
|
0
|
0
|
0
|
0
|
|
| Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
| Cashflow / Debt |
0.08
|
0.09
|
0.07
|
0.05
|
0.06
|
0.09
|
Details Astrazeneca
| Details |
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|
| Price |
4616.50
|
4437.50
|
5121.00
|
5873.00
|
7607.00
|
| Eps |
2.76
|
2.37
|
1.70
|
1.03
|
2.43
|
| Price/earnings-ratio |
1672.64
|
1872.36
|
3012.35
|
5701.94
|
4476.54
|
| Dividend |
2.70
|
2.74
|
2.75
|
2.89
|
2.83
|
| Dividend % |
0.06 %
|
0.06 %
|
0.05 %
|
0.05 %
|
0.03 %
|
| Payout % |
0.98
|
1.16
|
1.62
|
2.81
|
1.16
|
| Book value |
11.74
|
11.81
|
9.84
|
10.00
|
11.90
|
| Market to book |
0.0
|
0.0
|
0.0
|
0.0
|
|
| Cashflow per stock |
3.28
|
2.83
|
2.07
|
2.26
|
3.66
|
| Stocks |
1,265
|
1,266
|
1,267
|
1,312
|
1,313
|
| Market Cap |
5.840.931.62
|
5.618.858.39
|
6.488.511.84
|
7.706.198.22
|
14.279.224.26
|
Dividend Astrazeneca
Price info Astrazeneca
|
Date
|
Price
|
|---|---|
|
17 Apr 2024
|
10878.00
|
|
09 Apr 2024
|
10708.00
|
|
05 Apr 2024
|
10736.00
|
|
03 Apr 2024
|
10604.00
|
|
30 Mar 2024
|
10678.00
|
|
22 Mar 2024
|
10428.00
|
|
18 Mar 2024
|
10290.00
|
|
15 Mar 2024
|
10402.00
|
|
12 Mar 2024
|
10436.00
|
|
11 Mar 2024
|
10196.00
|
|
09 Mar 2024
|
10196.00
|
|
07 Mar 2024
|
10140.00
|
|
01 Mar 2024
|
9983.00
|
|
29 Feb 2024
|
10180.00
|
|
27 Feb 2024
|
10254.00
|
|
22 Feb 2024
|
10102.00
|
|
21 Feb 2024
|
10204.00
|
|
20 Feb 2024
|
10418.00
|
|
15 Feb 2024
|
9724.00
|
|
14 Feb 2024
|
9600.00
|
|
13 Feb 2024
|
9501.00
|
|
09 Feb 2024
|
9823.00
|
|
08 Feb 2024
|
9823.00
|
|
07 Feb 2024
|
10534.00
|
|
06 Feb 2024
|
10360.00
|
|
05 Feb 2024
|
10360.00
|
|
01 Feb 2024
|
10500.00
|
|
31 Jan 2024
|
10500.00
|
|
30 Jan 2024
|
10568.00
|
|
27 Jan 2024
|
10546.00
|
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
|
